Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/GMPS_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/GMPS_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GMPS_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GMPS_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GMPS_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GMPS_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GMPS_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00091242 | Oral cavity | OSCC | nucleoside monophosphate biosynthetic process | 29/7305 | 42/18723 | 7.73e-05 | 6.00e-04 | 29 |
GO:00091132 | Oral cavity | OSCC | purine nucleobase biosynthetic process | 10/7305 | 10/18723 | 8.14e-05 | 6.26e-04 | 10 |
GO:00091268 | Oral cavity | OSCC | purine nucleoside monophosphate metabolic process | 30/7305 | 44/18723 | 8.41e-05 | 6.44e-04 | 30 |
GO:007252120 | Oral cavity | OSCC | purine-containing compound metabolic process | 199/7305 | 416/18723 | 1.34e-04 | 9.53e-04 | 199 |
GO:000915020 | Oral cavity | OSCC | purine ribonucleotide metabolic process | 178/7305 | 368/18723 | 1.45e-04 | 1.02e-03 | 178 |
GO:00461122 | Oral cavity | OSCC | nucleobase biosynthetic process | 15/7305 | 18/18723 | 1.53e-04 | 1.07e-03 | 15 |
GO:000616320 | Oral cavity | OSCC | purine nucleotide metabolic process | 188/7305 | 396/18723 | 3.31e-04 | 2.04e-03 | 188 |
GO:00091562 | Oral cavity | OSCC | ribonucleoside monophosphate biosynthetic process | 23/7305 | 33/18723 | 3.47e-04 | 2.12e-03 | 23 |
GO:00091677 | Oral cavity | OSCC | purine ribonucleoside monophosphate metabolic process | 27/7305 | 41/18723 | 4.54e-04 | 2.74e-03 | 27 |
GO:00091123 | Oral cavity | OSCC | nucleobase metabolic process | 23/7305 | 34/18723 | 6.77e-04 | 3.78e-03 | 23 |
GO:19012938 | Oral cavity | OSCC | nucleoside phosphate biosynthetic process | 125/7305 | 256/18723 | 8.32e-04 | 4.41e-03 | 125 |
GO:00091658 | Oral cavity | OSCC | nucleotide biosynthetic process | 124/7305 | 254/18723 | 8.79e-04 | 4.63e-03 | 124 |
GO:004639017 | Oral cavity | OSCC | ribose phosphate biosynthetic process | 95/7305 | 190/18723 | 1.30e-03 | 6.46e-03 | 95 |
GO:00461481 | Oral cavity | OSCC | pigment biosynthetic process | 36/7305 | 62/18723 | 1.82e-03 | 8.57e-03 | 36 |
GO:00091272 | Oral cavity | OSCC | purine nucleoside monophosphate biosynthetic process | 15/7305 | 21/18723 | 2.65e-03 | 1.16e-02 | 15 |
GO:000926017 | Oral cavity | OSCC | ribonucleotide biosynthetic process | 88/7305 | 182/18723 | 6.29e-03 | 2.35e-02 | 88 |
GO:00061443 | Oral cavity | OSCC | purine nucleobase metabolic process | 13/7305 | 19/18723 | 9.07e-03 | 3.26e-02 | 13 |
GO:00091682 | Oral cavity | OSCC | purine ribonucleoside monophosphate biosynthetic process | 13/7305 | 19/18723 | 9.07e-03 | 3.26e-02 | 13 |
GO:00460377 | Oral cavity | NEOLP | GMP metabolic process | 7/2005 | 16/18723 | 7.62e-04 | 6.16e-03 | 7 |
GO:000916721 | Oral cavity | NEOLP | purine ribonucleoside monophosphate metabolic process | 11/2005 | 41/18723 | 3.12e-03 | 1.89e-02 | 11 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GMPS | SNV | Missense_Mutation | | c.472G>C | p.Asp158His | p.D158H | P49915 | protein_coding | tolerated(0.05) | benign(0.151) | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
GMPS | SNV | Missense_Mutation | | c.420N>G | p.Phe140Leu | p.F140L | P49915 | protein_coding | deleterious(0) | possibly_damaging(0.784) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
GMPS | SNV | Missense_Mutation | novel | c.207N>G | p.Phe69Leu | p.F69L | P49915 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GMPS | SNV | Missense_Mutation | | c.1783N>C | p.Ala595Pro | p.A595P | P49915 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
GMPS | SNV | Missense_Mutation | novel | c.91C>G | p.Leu31Val | p.L31V | P49915 | protein_coding | deleterious(0) | possibly_damaging(0.857) | TCGA-C5-A2LY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
GMPS | SNV | Missense_Mutation | | c.905N>T | p.Ser302Phe | p.S302F | P49915 | protein_coding | tolerated(0.06) | benign(0.127) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
GMPS | SNV | Missense_Mutation | rs879113982 | c.1913N>A | p.Arg638Gln | p.R638Q | P49915 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
GMPS | SNV | Missense_Mutation | novel | c.380N>C | p.Gly127Ala | p.G127A | P49915 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GMPS | SNV | Missense_Mutation | | c.1711N>T | p.Pro571Ser | p.P571S | P49915 | protein_coding | tolerated(0.27) | benign(0.063) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GMPS | SNV | Missense_Mutation | | c.2059N>A | p.Pro687Thr | p.P687T | P49915 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |